SignalXSignalX

KURA Kura Oncology, Inc.

8-K Current Report
Filed: March 5, 2026
Health Care
Pharmaceutical Preparations
Kura Oncology, Inc. Overview

Kura Oncology, Inc. (KURA) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

  • • Q4 and full-year 2025 financial results announced March 5, 2026 — full figures in Exhibit 99.1
  • • KURA is a clinical-stage oncology company; results likely reflect R&D spend, cash runway, and pipeline progress rather than product revenue

Get deeper insights on Kura Oncology, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.